HGH in Performance Protocols: What the Research Says

Human growth hormone (HGH) has been simultaneously overhyped and misunderstood for decades. In popular culture, it's associated with extreme bodybuilding and anti-aging clinics. In the research literature, it's a complex pleiotropic hormone with well-documented effects on body composition, recovery, and metabolic function.

This guide cuts through the noise and focuses on what the evidence actually shows.

HGH is a 191-amino acid peptide hormone produced by the anterior pituitary gland. It's released in pulses throughout the day, with the largest pulse occurring during deep sleep. Production peaks in adolescence and declines progressively with age — by the time most people reach their 40s, GH secretion is a fraction of what it was at 20.

The hormone acts both directly on target tissues and indirectly through insulin-like growth factor 1 (IGF-1), which is produced primarily in the liver in response to GH stimulation. Many of HGH's anabolic effects are actually mediated by IGF-1 rather than GH itself.

HGH directly stimulates lipolysis — the breakdown of stored fat — by activating hormone-sensitive lipase in adipose tissue. This is one of its most consistent and well-documented effects. GH preferentially mobilizes visceral fat, which is why GH-deficient adults tend to accumulate abdominal adiposity and GH replacement reverses this pattern.

HGH promotes nitrogen retention and protein synthesis, particularly in skeletal muscle. This effect is largely mediated through IGF-1. The combination of increased protein synthesis and decreased protein catabolism creates a net anabolic environment that supports muscle maintenance and growth.

HGH stimulates the production of collagen and other extracellular matrix proteins. This is particularly relevant for tendons and ligaments, which are often the limiting factor in athletic performance and recovery. GH-deficient adults have reduced tendon cross-sectional area and tensile strength; GH replacement normalizes these parameters.

GH is released primarily during slow-wave (deep) sleep. This creates a bidirectional relationship: adequate deep sleep drives GH release, and GH itself appears to promote deeper sleep. Optimizing this cycle is one of the most underappreciated aspects of recovery.

GH receptors are present on immune cells, and GH plays a role in immune regulation. GH-deficient individuals show impaired immune function that is partially restored by GH replacement.

Understanding HGH requires understanding IGF-1. When GH binds to receptors in the liver, it stimulates IGF-1 production. IGF-1 then circulates systemically and mediates many of GH's anabolic effects — particularly muscle protein synthesis and cell proliferation.

Serum IGF-1 is the primary biomarker used to assess GH status. Because GH is released in pulses and has a short half-life, measuring GH directly is impractical. IGF-1, which has a longer half-life and more stable serum levels, provides a reliable proxy for GH activity.

Target range: For performance optimization, most practitioners aim for IGF-1 levels in the upper quartile of the age-appropriate reference range. Supraphysiologic IGF-1 levels are associated with increased risk and are not the goal of a well-designed protocol.

The Vanguard Protocol uses HGH at doses calibrated to optimize the GH/IGF-1 axis without pushing into supraphysiologic territory. Dosing is individualized based on baseline IGF-1 levels and response.

Administration timing: HGH is typically administered before sleep to align with the natural nocturnal GH pulse, or in the morning in a fasted state to maximize lipolytic effects. The Vanguard Protocol uses pre-sleep administration to support recovery and sleep quality.

Injection site: Subcutaneous injection, rotating sites to prevent lipohypertrophy.

Monitoring: IGF-1 levels should be checked at baseline and at 4–6 week intervals during active use. Fasting glucose and insulin should also be monitored, as GH can cause transient insulin resistance.

It's worth being explicit about what HGH does not do at physiologic doses:

• It does not cause the dramatic muscle hypertrophy associated with anabolic steroids
• It does not produce rapid strength gains
• It does not work in isolation — its effects are most pronounced when combined with adequate training, nutrition, and sleep

HGH is a recovery and body composition compound, not a performance-enhancing drug in the traditional sense. Its value lies in optimizing the biological environment for adaptation, not in directly driving performance.

• IGF-1: Primary marker of GH axis activity. Check at baseline and every 4–6 weeks.
• Fasting glucose and insulin: Monitor for insulin resistance, particularly in the first 4–8 weeks.
• HOMA-IR: Calculated from fasting glucose and insulin; provides a composite measure of insulin sensitivity.
• Body composition: DEXA scan or bioelectrical impedance at baseline and 8–12 weeks.
• Sleep quality: Subjective sleep scores or wearable data (HRV, deep sleep percentage).

HGH occupies a specific niche in the Vanguard Protocol: it provides the systemic anabolic and lipolytic environment that amplifies the effects of the other compounds. BPC-157 and TB-500 drive local tissue repair; HGH ensures the systemic hormonal environment supports that repair process.

The combination of HGH with the recovery peptides creates a protocol that addresses both the local biology of tissue repair and the systemic hormonal context in which that repair occurs.

View the complete Vanguard Protocol →